Engage Therapeutics Announces Phase 2b StATES Study of Staccato® Alprazolam for Seizure Cessation Meets Primary Endpoint
March 12, 2020 00:02 ET
|
Engage Therapeutics
-- Staccato alprazolam achieved statistically significant response rate in both treatment arms compared to placebo ---- Average time to seizure cessation was 30 seconds ---- Staccato alprazolam...
Engage Therapeutics Announces Two Poster Presentations at the American Epilepsy Society’s Annual Meeting
December 04, 2019 08:00 ET
|
Engage Therapeutics
SUMMIT, N.J., Dec. 04, 2019 (GLOBE NEWSWIRE) -- Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing an orally inhaled benzodiazepine for the acute termination of an...
Engage Therapeutics to Present at the Stifel 2019 Healthcare Conference
November 12, 2019 08:05 ET
|
Engage Therapeutics
SUMMIT, N.J., Nov. 12, 2019 (GLOBE NEWSWIRE) -- /PRNewswire/ — Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing an orally inhaled benzodiazepine for the acute...
Engage Therapeutics to Present at the 21st Annual H.C. Wainwright Global Investment Conference
September 09, 2019 07:00 ET
|
Engage Therapeutics
SUMMIT, N.J., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing an inhaled benzodiazepine for the abortive treatment of seizures in...
Engage Therapeutics Announces Data from Phase 2a, Proof-of-concept Study of Staccato Alprazolam to Suppress Seizures in Patients with Epilepsy Published in Epilepsia
July 09, 2019 07:30 ET
|
Engage Therapeutics
– Staccato alprazolam shown to rapidly suppress seizure activity at two minutes in five patients with epilepsy –– Staccato alprazolam generally well tolerated; no serious or severe adverse events...
Bestselling Author Kurt Eichenwald to Lead Inspiring Discussion about Epilepsy and his Memior, ‘A Mind Unraveled’ Thursday, July 11, at 7 p.m. at Mayfair Hotel and Spa
July 01, 2019 07:25 ET
|
Engage Therapeutics
MIAMI, July 01, 2019 (GLOBE NEWSWIRE) -- New York Times bestselling author Kurt Eichenwald will be at the Mayfair Hotel and Spa in Coconut Grove on Thursday, July 11, at 7 p.m. to discuss his 2018...
Engage Therapeutics and Clinical Trial Network of Houston Host New York Times Bestselling Author Kurt Eichenwald for Inspiring Discussion about Overcoming Epilepsy
June 05, 2019 08:00 ET
|
Engage Therapeutics
HOUSTON, June 05, 2019 (GLOBE NEWSWIRE) -- New York Times bestselling author Kurt Eichenwald will be at Crowne Plaza Houston Near Reliant Medical on Thursday, June 13, at 7 p.m. to discuss his 2018...
Engage Therapeutics Presents Data from Part 1, Open-label Run-in of StATES Phase 2b Study of Staccato® Alprazolam at 2019 American Academy of Neurology Annual Meeting
May 06, 2019 07:30 ET
|
Engage Therapeutics
– Eight (8) patients with predictable generalized or focal epileptic seizures treated with Staccato alprazolam – – 62.5 percent of patients respond with cessation of seizure activity within two...
Engage Therapeutics to Present Phase 2b Open Label Run-in Data from StATES Trial of Staccato Alprazolam at 2019 American Academy of Neurology Annual Meeting
March 13, 2019 07:30 ET
|
Engage Therapeutics
SUMMIT, N.J., March 13, 2019 (GLOBE NEWSWIRE) -- Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a Rapid Epileptic Seizure Termination (REST) therapy for people who...
Engage Therapeutics Successfully Completes Open Label Portion of Phase 2b StATES Study and Begins Enrollment in Double-Blind Placebo-Controlled Portion
December 03, 2018 07:00 ET
|
Engage Therapeutics
Trial evaluating safety and efficacy of Staccato Alprazolam in subjects with epilepsy and a predictable seizure pattern Results from the open label portion of the study will be presented at a major...